JP7530904B2 - 特異的結合性分子 - Google Patents

特異的結合性分子 Download PDF

Info

Publication number
JP7530904B2
JP7530904B2 JP2021544406A JP2021544406A JP7530904B2 JP 7530904 B2 JP7530904 B2 JP 7530904B2 JP 2021544406 A JP2021544406 A JP 2021544406A JP 2021544406 A JP2021544406 A JP 2021544406A JP 7530904 B2 JP7530904 B2 JP 7530904B2
Authority
JP
Japan
Prior art keywords
binding molecule
specific binding
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021544406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523507A5 (cg-RX-API-DMAC7.html
JP2022523507A (ja
Inventor
コネストラーロ,マルティナ
ディークマン,ネレ
ハーパー,スティーブン
ベネディクト カーク,ピーター
マルバニー,レイチェル
オドワイヤー,ローナン
バトラー ロバートソン,イアン
Original Assignee
イムノコア リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムノコア リミテッド filed Critical イムノコア リミテッド
Publication of JP2022523507A publication Critical patent/JP2022523507A/ja
Publication of JP2022523507A5 publication Critical patent/JP2022523507A5/ja
Application granted granted Critical
Publication of JP7530904B2 publication Critical patent/JP7530904B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2021544406A 2019-01-30 2020-01-30 特異的結合性分子 Active JP7530904B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1901305.1 2019-01-30
GBGB1901305.1A GB201901305D0 (en) 2019-01-30 2019-01-30 Specific binding molecules
PCT/EP2020/052315 WO2020157210A1 (en) 2019-01-30 2020-01-30 Cd3-specific binding molecules

Publications (3)

Publication Number Publication Date
JP2022523507A JP2022523507A (ja) 2022-04-25
JP2022523507A5 JP2022523507A5 (cg-RX-API-DMAC7.html) 2023-03-10
JP7530904B2 true JP7530904B2 (ja) 2024-08-08

Family

ID=65997940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021544406A Active JP7530904B2 (ja) 2019-01-30 2020-01-30 特異的結合性分子

Country Status (12)

Country Link
US (1) US12590152B2 (cg-RX-API-DMAC7.html)
EP (1) EP3917959A1 (cg-RX-API-DMAC7.html)
JP (1) JP7530904B2 (cg-RX-API-DMAC7.html)
KR (1) KR102984612B1 (cg-RX-API-DMAC7.html)
CN (1) CN113728005B (cg-RX-API-DMAC7.html)
AU (1) AU2020215776A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021014963A2 (cg-RX-API-DMAC7.html)
CA (1) CA3127144A1 (cg-RX-API-DMAC7.html)
GB (1) GB201901305D0 (cg-RX-API-DMAC7.html)
IL (1) IL284926B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021009275A (cg-RX-API-DMAC7.html)
WO (1) WO2020157210A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CN117964777A (zh) * 2021-08-26 2024-05-03 瑅安生物医药(杭州)有限公司 一种接近天然分子的多肽融合分子
JP2025508738A (ja) 2022-02-20 2025-04-10 イムノコア リミテッド Hiv特異的結合分子及びtcr
TW202423994A (zh) 2022-08-18 2024-06-16 英商英美偌科有限公司 多域結合分子
KR20250133715A (ko) 2023-01-06 2025-09-08 이뮤노코어 리미티드 Prame 펩타이드-hla 복합체에 대한 결합 분자
IL321809A (en) 2023-01-06 2025-08-01 Immunocore Ltd Binding molecules against a piwil1 peptide-hla complex
TW202519257A (zh) * 2023-08-01 2025-05-16 英商英美偌科有限公司 治療皮膚黑色素瘤之方法
WO2025050404A1 (zh) * 2023-09-08 2025-03-13 成都维瑾柏鳌生物医药科技有限公司 一种药物组合物及其应用
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand
GB202418912D0 (en) 2024-12-20 2025-02-05 Immunocore Ltd Specific binding molecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234319A1 (en) 2017-06-20 2018-12-27 Immunocore Limited LYMPHOCYTE T RECEPTORS

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36676A (en) 1862-10-14 Improvement in grain-cleaners
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
AU7757581A (en) 1980-11-19 1982-05-27 United Energy Technologies Inc. Enhanced surface tubing
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS5855530Y2 (ja) 1981-06-15 1983-12-20 松下電工株式会社 照明器具を有する天井
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP1791865B1 (en) 2004-06-29 2010-07-28 Immunocore Ltd. Cells expressing a modified t cell receptor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
BR112015000798A2 (pt) 2012-07-13 2017-06-27 Zymeworks Inc heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
HUE050159T2 (hu) 2013-12-17 2020-11-30 Genentech Inc Anti-CD3 antitestek és alkalmazási eljárások
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
GB201522592D0 (en) 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
IL308831A (en) 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
GB202006629D0 (en) * 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
US12103971B2 (en) * 2022-02-20 2024-10-01 Immunocore Limited HIV specific binding molecules
WO2024038165A1 (en) * 2022-08-18 2024-02-22 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
KR20250133715A (ko) * 2023-01-06 2025-09-08 이뮤노코어 리미티드 Prame 펩타이드-hla 복합체에 대한 결합 분자
IL321809A (en) * 2023-01-06 2025-08-01 Immunocore Ltd Binding molecules against a piwil1 peptide-hla complex

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234319A1 (en) 2017-06-20 2018-12-27 Immunocore Limited LYMPHOCYTE T RECEPTORS

Also Published As

Publication number Publication date
AU2020215776A1 (en) 2021-09-09
KR20210121141A (ko) 2021-10-07
BR112021014963A2 (pt) 2021-09-28
IL284926B1 (en) 2025-11-01
US12590152B2 (en) 2026-03-31
WO2020157210A1 (en) 2020-08-06
IL284926B2 (en) 2026-03-01
US20220119527A1 (en) 2022-04-21
CA3127144A1 (en) 2020-08-06
GB201901305D0 (en) 2019-03-20
CN113728005B (zh) 2025-02-21
IL284926A (en) 2021-09-30
CN113728005A (zh) 2021-11-30
MX2021009275A (es) 2021-08-16
KR102984612B1 (ko) 2026-07-02
EP3917959A1 (en) 2021-12-08
JP2022523507A (ja) 2022-04-25

Similar Documents

Publication Publication Date Title
CN113728005B (zh) Cd3特异性结合分子
US11859004B2 (en) Anti-human 4-1BB antibodies and uses thereof
JP7720685B2 (ja) T細胞レセプター
JP7143452B2 (ja) CD47とSIRPaの相互作用を遮断できる抗体及びその応用
US11518808B2 (en) Anti-PD-1 antibodies and methods of treatment
CN107223135B (zh) 用于治疗hbv感染和相关病症的三特异性结合分子
JP2020018298A (ja) Cldn18.2及びcd3に対する抗体コンストラクト
JP2022101631A (ja) 抗pd‐l1抗体とil‐7との融合
CN118878694A (zh) 一种双特异性抗体及其用途
JP2019514871A (ja) 骨髄性白血病の治療方法で使用するための、cd33とcd3に結合する二重特異性構築物の投与の方法
JP2025170264A (ja) 抗bcma剤のための投与レジメン
TW201916890A (zh) 抗pd-1抗體和抗lag-3抗體聯合在製備治療腫瘤的藥物中的用途
CN109929037B (zh) 针对程序性死亡配体的结合物及其应用
WO2019192493A1 (zh) 抗人lag-3单克隆抗体及其应用
US20210277139A1 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
WO2023236991A1 (zh) 靶向her2,pd-l1和vegf的三特异性抗体
JP7849048B2 (ja) Cd25偏向抗il-2抗体
WO2024235317A1 (zh) 结合lilrb4和cd3的抗体及其用途
RU2826453C2 (ru) Cd3-специфические связывающие молекулы
WO2023052541A1 (en) Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
TW202235436A (zh) Siglec-15結合蛋白的製備及其用途
HK40059424B (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
HK40037194A (en) Anti-pd-1 antibodies and methods of treatment
HK40037194B (en) Anti-pd-1 antibodies and methods of treatment

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20221128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240415

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240729

R150 Certificate of patent or registration of utility model

Ref document number: 7530904

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150